Grünenthal said the FDA granted Orphan Drug and Rare Pediatric Disease Designations for its investigational compound tegacorat (GRM-01) in Duchenne muscular dystrophy (DMD). The designations support potential incentives for development/approval, which is a positive milestone for the program even though no efficacy or financial figures were provided.
Grünenthal said the FDA granted Orphan Drug and Rare Pediatric Disease Designations for its investigational compound tegacorat (GRM-01) in Duchenne muscular dystrophy (DMD). The designations support potential incentives for development/approval, which is a positive milestone for the program even though no efficacy or financial figures were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
